NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

NCT03971253

CompletedN/A

Sponsor: Astellas Pharma Inc

Conditions: Rheumatoid Arthritis (RA)

Interventions: Peficitinib

Countries: Japan

The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.

Exclusion Criteria:

* Not applicable.

Locations (47)

Aichi, Japan
Akita, Japan
Aomori, Japan
Chiba, Japan
Ehime, Japan
Fukui, Japan
Fukuoka, Japan
Fukushima, Japan
Gifu, Japan
Gunma, Japan
Hiroshima, Japan
Hokkaido, Japan
Hyōgo, Japan
Ibaraki, Japan
Ishikawa, Japan
Kagawa, Japan
Kagoshima, Japan
Kanagawa, Japan
Kochi, Japan
Kumamoto, Japan
Kyoto, Japan
Mie, Japan
Miyagi, Japan
Miyazaki, Japan
Nagano, Japan
Nagasaki, Japan
Nara, Japan
Niigata, Japan
Numakunai, Japan
Okayama, Japan
+ 17 more on CT.gov